REGENXBIO Inc.RGNXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank25
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-126.38M
↓ 46% vs avg
Percentile
P25
Within normal range
Streak
3 yr
Consecutive growthContracting
Average
$-86.47M
Historical baseline
PeriodValueYoY Change
TTM$-126.38M+28.0%
2024$-175.56M+23.1%
2023$-228.37M+4.1%
2022$-238.21M-276.8%
2021$134.70M+266.4%
2020$-80.93M+32.2%
2019$-119.42M-230.7%
2018$91.37M+240.2%
2017$-65.15M-14.9%
2016$-56.71M-